Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News

More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 22, 2021
News
Long-term metformin use linked to fewer ER+ breast cancers
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 8, 2021
News

Oily fish linked to lower risk of diabetes in largest study to date
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 4, 2021
News

PURE: High refined-grain intake boosts death, CVD events
- Author:
- Mitchel L. Zoler, PhD
Publish date: February 3, 2021
News

Widespread liver disease missed in patients with T2D
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 22, 2021
News

Cardiometabolic Center Alliance promotes multiorgan, integrated T2D treatment
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 20, 2021
News
Sotagliflozin’s trial data receives FDA welcome for NDA filing
- Author:
- Mitchel L. Zoler, PhD
Publish date: January 14, 2021
News
Far too few with treatment-resistant hypertension get hormone test
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 31, 2020
News
Twincretin ‘impressive’: Topline data from phase 3 trial in diabetes
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 14, 2020
News

FDA approves liraglutide for adolescents with obesity
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 10, 2020
News

Obesity phenotyping matches patients with more effective interventions
- Author:
- Mitchel L. Zoler, PhD
Publish date: December 4, 2020
Article

Finerenone’s heart benefits hold up in T2D patients without CVD
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 24, 2020
News

First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 18, 2020
News

VTEs tied to immune checkpoint inhibitor cancer treatment
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 17, 2020
News
Evinacumab, novel lipid-lowerer, extends promise in phase 2 results
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 15, 2020